RECOGNIZING WOMEN IN IMMUNE-DRIVEN MEDICINE
This Women's History Month, we want to help even more women scientists make history.
At Adaptive, we’re committed to promoting the work and accomplishments of women scientists across the field of immune-driven medicine. We believe more perspectives and diversity not only helps us as a company, but also advances immune-driven medicine as a whole, improving millions of lives along the way.
To make this mission a reality, we’re announcing our first-ever immunoSEQ Women in Immune-Driven Medicine (WIDEN) Award. Our scientific committee will select one or more winners to receive a $5,000 grant to use for sequencing to assist in their research. Research proposals must be submitted by June 30th, 2021, to be considered.
Ready to submit a project proposal?
Current recipient 2020
Inimary Toby, PhD, University of Dallas, TX
Research Summary: Acute respiratory distress syndrome (ARDS) affects approximately 190,600 individuals per year in the United States, with mortality up to 45%. Localized inflammatory processes are detectable during ARDS, with previous studies indicating that T cells contribute to an aberrant response, which leads to excessive tissue damage and eventually ARDS. Using the immunoSEQ Technology, we hypothesize that there are populations of responder and non-responder T-cell receptors amongst individuals diagnosed with ARDS, which can be tracked and leveraged to gain insights into the adaptive immune repertoire of ARDS. We believe these TCRs could serve as ARDS biomarkers and that understanding these would enable us to identify CDR3 sequence patterns associated with ARDS.
immunoSEQ Assays are for Research Use Only. Not for use in diagnostic procedures.